Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Neoadjuvant Immunotherapy in HPV-Driven Oropharynx Cancer
NCT03838263Phase 2Completed
- Sponsor
- Unicancer
- Start
- Jul 2019
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Unicancer. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT03838263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03838263.